Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure

BACKGROUND: Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic infection. In non-HIV immunocompromised patients with PCP, a standard second-line treatment has not been established up to now. METHODS: Non-HIV immunocompromised patients with confirmed PCP between April 2013 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Anlei, Sun, Ruixue, Cao, Guanghui, Liu, Xiaohang, Zhu, Huadong, Yang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199170/
https://www.ncbi.nlm.nih.gov/pubmed/35701759
http://dx.doi.org/10.1186/s12879-022-07523-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9199170/
https://www.ncbi.nlm.nih.gov/pubmed/35701759
http://dx.doi.org/10.1186/s12879-022-07523-y

Ejemplares similares